Vortioxetine: Difference between revisions

(One intermediate revision by the same user not shown)

Line 14:

| pregnancy = Limited data; weigh benefits/risks

| legal = Rx

| intro = '''Vortioxetine''' (brand name Trintellix in the US, formerly Brintellix) is a multimodal antidepressant FDA-approved in 2013 for major depressive disorder. Beyond SERT inhibition, it directly modulates multiple serotonin receptor subtypes: 5HT1A agonism, 5HT1B partial agonism, and 5HT3, 5HT7, and 5HT1D antagonism. This combination produces, via disinhibition, downstream increases in not only serotonin but also norepinephrine, dopamine, acetylcholine, histamine, and glutamate — the hypothesized basis for its '''pro-cognitive effects''' (improved processing speed) that have distinguished it in trials of MDD with cognitive symptoms.

| intro = '''Vortioxetine''' (brand name Trintellix in the US, formerly Brintellix) is a multimodal antidepressant FDA-approved in 2013 for major depressive disorder. Beyond SERT inhibition, it directly modulates multiple serotonin receptor subtypes: 5HT1A agonism, 5HT1B partial agonism, and 5HT3, 5HT7, and 5HT1D antagonism. This combination produces, via disinhibition, downstream increases in not only serotonin but also norepinephrine, dopamine, acetylcholine, histamine, and glutamate, the hypothesized basis for its '''pro-cognitive effects''' (improved processing speed) that have distinguished it in trials of MDD with cognitive symptoms.

The ondansetron-like 5HT3 antagonism reduces the GI side effects common to pure SSRIs (less nausea than typical SERT inhibitors). Sexual side effects appear to be lower than with SSRIs but still occur.

Line 25:

[[Category:Multimodal Serotonergic Agents]]

[[Category:Multimodal Antidepressants]]

~~[[Category:Serotonin Reuptake Inhibitors]]~~

MDElliottMD (talk | contribs)